Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.8K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.8K
Ion-Exchange Chromatography01:09

Ion-Exchange Chromatography

1.3K
Ion-exchange chromatography, or IEC, is a technique for separating ions based on their affinity for the stationary phase. The stationary phase is a cross-linked polymer resin with covalently attached ionic functional groups. The functional groups can be either positively charged (cation exchangers) or negatively charged (anion exchangers). A cation exchanger consists of a polymeric anion and active cations, while an anion exchanger is a polymeric cation with active anions. The choice of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Impact on Cost and Expert Time of Data-Efficient Deep Learning for Medical Image Segmentation.

Radiology. Artificial intelligence·2026
Same author

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.

Experimental hematology & oncology·2026
Same author

Energy-resolved attenuation behaviour on dual-source photon-counting CT: Implications for quantitative assessment of femoral bone marrow in multiple myeloma.

European journal of radiology·2026
Same author

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.

European urology oncology·2026
Same author

AI-BLADE toolbox: AI-powered BLADdEr multiparametric MRI analysis for clinical application.

BJR artificial intelligence·2026
Same journal

When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

Evaluation of audiovisual and auditory interventions on exam anxiety during whole-body magnetic resonance imaging in cancer patients: a quasi-experimental study.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [<sup>68</sup>Ga]GaPSMA-PET/CT for [<sup>177</sup>Lu]LuPSMA therapy in metastatic prostate cancer (mCRPC).

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

Correction to: [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

MRI-based perfusion-diffusion habitat analysis for characterizing intratumoral heterogeneity in rectal adenocarcinoma.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

Survival prediction of <sup>18</sup>F-FDG PET/CT in pediatric patients with recurrent neuroblastoma.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
See all related articles

Related Experiment Video

Updated: Nov 20, 2025

Author Spotlight: Advancements in Impedance Monitoring for Cochlear Implant Surgery
06:54

Author Spotlight: Advancements in Impedance Monitoring for Cochlear Implant Surgery

Published on: August 4, 2023

1.5K

iRECIST: how to do it.

Thorsten Persigehl1, Simon Lennartz2,3, Lawrence H Schwartz4

  • 1Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Kerpener Straße 62, 50937, Cologne, Germany. thorsten.persigehl@uk-koeln.de.

Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|January 5, 2020
PubMed
Summary
This summary is machine-generated.

Immune-checkpoint inhibitors (ICIs) are revolutionizing cancer care. The immune Response Criteria (iRECIST) provides updated guidelines for assessing patient response to these novel immunotherapies.

Keywords:
ImmunotherapyPseudoprogressionResponse evaluationTherapy monitoringiRECIST

More Related Videos

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.3K
Electrophoretic Mobility Shift Assay EMSA for the Study of RNA-Protein Interactions: The IRE/IRP Example
12:44

Electrophoretic Mobility Shift Assay EMSA for the Study of RNA-Protein Interactions: The IRE/IRP Example

Published on: December 3, 2014

54.4K

Related Experiment Videos

Last Updated: Nov 20, 2025

Author Spotlight: Advancements in Impedance Monitoring for Cochlear Implant Surgery
06:54

Author Spotlight: Advancements in Impedance Monitoring for Cochlear Implant Surgery

Published on: August 4, 2023

1.5K
Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.3K
Electrophoretic Mobility Shift Assay EMSA for the Study of RNA-Protein Interactions: The IRE/IRP Example
12:44

Electrophoretic Mobility Shift Assay EMSA for the Study of RNA-Protein Interactions: The IRE/IRP Example

Published on: December 3, 2014

54.4K

Area of Science:

  • Oncology
  • Radiology
  • Immunotherapy

Background:

  • Immune-checkpoint inhibitors (ICIs) represent a significant advancement in cancer treatment, particularly for advanced metastatic diseases.
  • The growing application of ICIs, often in combination with chemotherapy, necessitates specialized response assessment criteria.
  • Atypical response patterns like pseudoprogression and unique adverse reactions associated with ICIs require careful radiologic interpretation.

Purpose of the Study:

  • To provide guidance on response assessment for oncologic patients undergoing immunotherapy.
  • To detail the application of the immune Response Criteria (iRECIST) for objective monitoring of immunotherapies.

Main Methods:

  • The study is based on the iRECIST criteria, published in 2017 by the RECIST working group.
  • iRECIST is an adaptation of RECIST 1.1, originally developed for cytotoxic therapies and targeted agents.
  • The criteria are designed to address the unique challenges of assessing immunotherapy response, including pseudoprogression.

Main Results:

  • The iRECIST criteria offer an objective framework for monitoring treatment efficacy in patients receiving immunotherapies.
  • Understanding atypical response patterns and imaging findings is crucial for accurate assessment.

Conclusions:

  • This article offers essential guidance for radiologists and oncologists on utilizing iRECIST for immunotherapy response evaluation.
  • Adherence to iRECIST facilitates consistent and accurate assessment of treatment outcomes in patients on immunotherapy.